Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant

Lemborexant, a dual orexin receptor antagonist, is approved in the United States, Japan, and Canada for the treatment of insomnia in adults. This phase I, multicenter, open‐label, parallel‐group study assessed the impact of mild or moderate hepatic impairment (HI) on lemborexant pharmacokinetics and...

Descripción completa

Detalles Bibliográficos
Autores principales: Dayal, Satish, Aluri, Jagadeesh, Hall, Nancy, Filippov, Gleb, Moline, Margaret, Reyderman, Larisa, Landry, Ishani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023329/
https://www.ncbi.nlm.nih.gov/pubmed/33822479
http://dx.doi.org/10.1002/prp2.758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023329/
https://www.ncbi.nlm.nih.gov/pubmed/33822479
http://dx.doi.org/10.1002/prp2.758

Ejemplares similares